Key result
PCSK9i temporarily lowers inflammatory markers NLR and MLR at 3 months in HoFH.
Cohort (n=25)
Answers are grounded in this paper and cite their sources.
Prospective cohort study finds PCSK9 inhibition transiently lowers inflammatory cell ratios in homozygous familial hypercholesterolemia, suggesting a lipid-independent mechanism.
Background and aims: Extremely elevated levels of low-density lipoprotein-cholesterol (LDL-C) contribute to long-term chronic systemic inflammation in homozygous familial hypercholesterolemia (HoFH) patients. The aims of this study is to describe the inflammatory profile of HoFH patients and explore the effect of a PCSK9 inhibitor (PCSK9i) on a series of inflammatory biomarkers, including the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-HDL ratio (MHR), monocyte-lymphocyte ratio (MLR) and mean platelet volume-lymphocyte ratio (MPVLR). Methods: In this prospective cohort study, 25 definitive HoFH patients on high-intensity statins plus ezetimibe were administered subcutaneous injections of 420 mg PCSK9i every 4 weeks (Q4W). The biochemical parameters and inflammatory profile were analyzed on the day before PCSK9i therapy and 3 months and 6 months after PCSK9i therapy. Results: HoFH on the maximum tolerated statin dose plus ezetimibe displayed elevated lipid and disturbed blood biomarker profiles. After 3 months of add-on PCSK9i therapy, a significant reduction in LDL-C was observed. Moreover, the percentage and count of neutrophils, monocyte counts, MPV, and two inflammatory biomarkers, the NLR and MLR, were reduced. However, at 6 months of PCSK9i treatment, the NLR and MLR returned to pre-PCSK9i treatment levels. Conclusions: PCSK9i induces a transient decrease in the NLR and MLR in HoFH patients in a lipid-lowering independent manner.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a cohort in Homozygous familial hypercholesterolemia (HoFH) (n=25). PCSK9 inhibitor (PCSK9i) vs. Baseline (pre-PCSK9i treatment levels) was evaluated on Inflammatory biomarkers including neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-lymphocyte ratio (PLR), monocyte-HDL ratio (MHR), and mean platelet volume-lymphocyte ratio (MPVLR). Subcutaneous PCSK9i reduced LDL-C, NLR, and MLR at 3 months in 25 HoFH patients, though NLR and MLR returned to baseline by 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: